Unveiling the role of m6A modification in esophageal cancer: a new frontier in tumor innate interferon immunity
Authors:
Open Access
- 18 November 2025
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 25 (1) , 412
Abstract
Esophageal cancer (ESCA) is one of the most common and aggressive malignancies worldwide and has a poor prognosis in its late stages, posing a significant threat to human health. N6-methyladenosine (m6A) is the most prevalent RNA chemical modification in eukaryotes, which has gained substantial attention for its critical role in regulating RNA stability, splicing, translation, and localization. Although m6A modification has been found implicated in the initiation and progression of various cancers, its specific mechanisms in ESCA remain underexplored. Concurrently, it's well-recognized that innate immunity is the body's first line of defense against pathogens, playing a vital role in tumor immune surveillance. Additionally, m6A modification has been shown to regulate multiple key innate immune signaling pathways, including the cGAS-STING, Toll-like receptor (TLR), and RIG-I-like receptor (RLR) pathways, which are integral to immune responses and closely linked to several diseases. However, the exact role of m6A in modulating these innate immune pathways in ESCA remains largely unclear. Therefore, this review aimed to explore the interplay between m6A modification and innate immune signaling in ESCA. The findings of this article may provide novel insights into the role of m6A in immune evasion and lay a solid foundation for developing novel immunotherapeutic strategies.Keywords
Funding Information
- Key Research Project of Sichuan Province (No.2023YFS0199)
- Chengdu science and technology project (No.2022-YF05-01833-SN)
- Sichuan Cadre Health Care Research Project (GBKT23020)
This publication has 142 references indexed in Scilit:
- Genome‐wide profiling of N6‐methyladenosine‐modified pseudogene‐derived long noncoding RNAs reveals the tumour‐promoting and innate immune‐restraining function of RPS15AP12 in ovarian cancerClinical and Translational Medicine, 2025
- The tumor cell-intrinsic cGAS–STING pathway is associated with the high density of CD8+ T cells after chemotherapy in esophageal squamous cell carcinomaEsophagus, 2024
- METTL3 ‐mediated m6A modification of EPPK1 to promote the development of esophageal cancer through regulating the PI3K / AKT pathwayEnvironmental Toxicology, 2024
- N6‐methyladenosine (m6A) modification in gynecological malignanciesJournal of Cellular Physiology, 2022
- FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cellsClinical & Experimental Metastasis, 2022
- A methyltransferase‐like 14/miR‐99a‐5p/tribble 2 positive feedback circuit promotes cancer stem cell persistence and radioresistance via histone deacetylase 2‐mediated epigenetic modulation in esophageal squamous cell carcinomaClinical and Translational Medicine, 2021
- Recent progress in multidisciplinary treatment for patients with esophageal cancerSurgery Today, 2019
- Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathwayCellular and Molecular Life Sciences, 2017
- Toll-like receptor 4 activation in Barrett’s esophagus results in a strong increase in COX-2 expressionJournal of Gastroenterology, 2013
- Treatments for esophageal cancer: a reviewGeneral Thoracic and Cardiovascular Surgery, 2013